Background

It is reasonable to think that cancer patients undergoing chemotherapy, targeted therapy or immunotherapy could have a more aggressive course if positive for Coronavirus disease CoV-2 (COVID- 19).

Methods

We conducted a literature review on https://www.ncbi.nlm.nih.gov/pubmed/, https://scholar.google.com, www.arxiv.org, www.biorxiv.org, of all articles published using the keywords COVID-19 therapy or treatment and cancer until May 2, 2020. A total of 205 articles were identified and 53 were included in this review.

Results

We describe the ongoing COVID-19 therapies that should be known by oncologists and highlight the potential interactions with antineoplastic drugs, commonly used in clinical practice. The main drug interactions were found with tocilizumab, ruxolitinib and colchicine. Conclusions. The literature provides an inconclusive picture on potential preferred treatments for COVID-19 and their interactions with antineoplastic agents. Future clinical trials are needed to better understand the interactions between different drugs in the context of COVID-19 pandemic.

中文翻译：

---

COVID 19 疗法和抗癌药物：近期文献的系统回顾。

 背景

有理由认为，如果冠状病毒疾病 CoV-2 (COVID-19) 呈阳性，接受化疗、靶向治疗或免疫治疗的癌症患者可能会出现更具侵袭性的病程。

 方法

我们对 https://www.ncbi.nlm.nih.gov/pubmed/、https://scholar.google.com、www.arxiv.org、www.biorxiv.org 上发表的所有文章进行了文献综述关键词“COVID-19 治疗或治疗和癌症”截止日期为 2020 年 5 月 2 日。共识别出 205 篇文章，其中 53 篇纳入本次综述中。

 结果

我们描述了肿瘤学家应该了解的正在进行的 COVID-19 疗法，并强调了与临床实践中常用的抗肿瘤药物的潜在相互作用。主要药物相互作用是托珠单抗、鲁索替尼和秋水仙碱。结论。文献对 COVID-19 的潜在首选治疗方法及其与抗肿瘤药物的相互作用提供了不确定的描述。未来需要进行临床试验，以更好地了解在 COVID-19 大流行背景下不同药物之间的相互作用。